期刊文献+

生物反应器培养分泌重组人干扰素β1a的CHO细胞工艺的建立 被引量:2

Development of procedure for culture of CHO cells secreting recombinant human interferon β1a in bioreactor
原文传递
导出
摘要 目的建立生物反应器培养分泌重组人干扰素β1a(IFNβ1a)的CHO细胞的工艺,探讨CHO细胞表达分泌IFNβ1a的反应动力学规律。方法应用15 L生物反应器悬浮微载体方式培养CHO工程细胞,比较不同时期细胞的生长形态、数量、生物活性、灌流量、葡萄糖消耗量及其他物理参数的变化规律。结果 15 L生物反应器中在初始pH 6.86~7.20,溶氧30%~70%,温度36.8~37.2℃,微载体4 g/L,罐流量6.5 L/h的条件下连续培养40 d,CHO工程细胞的密度维持在5×105个/ml之间,收获的细胞液中重组人IFNβ1a的生物活性为2.5×104~4.0×105IU/ml,葡萄糖消耗量在0.5~2.5 mg/ml之间。结论初步建立了15 L生物反应器培养分泌重组人IFNβ1a的CHO细胞的工艺,为进一步建立工业化生产工艺奠定了基础。 Objective To develop a procedure for culture of Chinese hamster ovary (CHO) cells secreting recombinant human interferon β1a (IFNβ1a) in bioreactor and investigate the kinetic regularity of secretion of IFNβ1a. Methods CHO cells were subjected to suspension culture on microcarriers in 15 L bioreactor, of which the growth, count, biological activity, perfusion rate, glucose consummation and other physical parameters were evaluated. Results The density of CHO cells reached 5 × 105 cells/ml after culture in 15 L bioreactor at initial pH value of 6. 86 ~ 7. 20, dissolved oxy- gen content of 30% ~ 70%, temperature of 36. 8 - 37.2 ℃, microcarrier content of 4 g/L and flow rate of 6. 5 L/h for 40 d, while the biological activity of recombinant human IFNβ1a in harvested cells was 2. 5 × 104 - 4. 0 × 105 IU/ml, and the glucose consumption was O. 5 ~ 2. 5 mg / ml. Conclusion A procedure for culture of CHO cells secreting recombi- nant human IFNβ1a in 15 L bioreactor was preliminarily developed, which laid a foundation of further development of large-seale oroduetion procedure of IFNβ1a.
出处 《中国生物制品学杂志》 CAS CSCD 2013年第10期1493-1497,共5页 Chinese Journal of Biologicals
基金 广东省教育部产学研结合项目(2012B091100408) 深圳市科技创新委资助项目(2112K3070011 JAS2009032012-00A)
关键词 生物反应器 微载体 中国仓鼠卵巢细胞 干扰素β1a 无血清培养基 Bioreactor Microcarriers Chinese hamster ovary (CHO) cells Interferon 131a Serum-free medium
  • 相关文献

参考文献12

  • 1Van Beers MM, Sauerborn M, Gilli F, et al. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta [J]. J Immunol Me- thods, 2010, 352 (1-2): 32-37.
  • 2Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treat- ment of MS with IFN beta-lb or glatiramer acetate by monthly brain MRI in the BECOME study [J]. Neurology, 2009, 72 (23): 1976-1983.
  • 3Zhang J, Hutton G, Zang Y. of action of interferon beta treatment of multiple sclerosis 1998-2021.
  • 4A comparison of the mechanisms and glatiramer acetate in the [J]. Clin Ther, 2002, 24 (12): Javed A, Reder AT. Therapeutic role of beta-interferons in muhiple sclerosis [J]. Pharmacol Ther, 2006, 110 ( 1 ) : 35-56.
  • 5谢琰臣,张华,许贤豪.干扰素-β治疗多发性硬化[J].中国神经免疫学和神经病学杂志,2006,13(2):124-127. 被引量:10
  • 6刘运龙,程远国,刘学龙.干扰素研究进展[J].动物医学进展,2008,29(2):85-89. 被引量:35
  • 7王妍,黄志立,李艳晖,张丽君,解桂秋.干扰素β1a基因真核表达质粒的构建和表达[J].吉林大学学报(医学版),2013,39(2):204-208. 被引量:1
  • 8Brezinsky SC, Chiang GG, Szilvasi A, et d. A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity [J]. J Immunol Methods, 2003, 277 (1-2) : 141-155.
  • 9申烨华,耿信笃.CHO细胞表达系统研究新进展[J].生物工程进展,2000,20(4):23-25. 被引量:41
  • 10史艳秋,陈畅,顾黎,邹思湘,宋静,王鹏.重组人β干扰素在DHFR^--CHO细胞中的高效表达[J].中国生化药物杂志,2006,27(3):129-133. 被引量:7

二级参考文献74

共引文献84

同被引文献37

  • 1曾国华,陈贻锴,J.shevitz.抗人A血型杂交瘤细胞高密度培养条件的研究[J].中国生物制品学杂志,1991,4(2):75-77. 被引量:1
  • 2Ribatti D. From the discovery d monoclonal antibodies to their thetic application: an historical reappraisal [ J ]. Immunol Lett, 2014, 161(1) : 96 -99.
  • 3Rastogi A, Tan SH, Banerjee S, et al. ERG monoclonal antibody in the diagnosis andbiological stratification of prostate cancer: delineation of minimal epitope, critical residues for binding, and molecular basis of specificity [ J ]. Monoclon Antib Immunodiagn Immunother, 2014, 33(4): 201 -208.
  • 4Li X, Iida M, Tada M, et al. Development of an anti-elaudin-3 and -4 bispeeifie monoclonal antibody for cancer diagnosis and therapy [J]. J Phannacol Exp Ther, 2014, 351(1) : 206 -213.
  • 5Pamnani R. Irmmmophenotyping of acute leukaemias by flow cytometry: a review[J]. East Aft: Med J, 2009, 86(12 Suppl) : $89 -$92.
  • 6Kato Y, Kaneko MK. A cce-specitlc rzonoclonal anfib(x reccgniz the aberrantly glycesylated podoplanin[J/OL]. Sci Rep, 2014, 4: 5924.
  • 7Liu JK. The history of monoclonal antibody development-Progress, remaining challenges and future innovations [ J ]. Ann Med Surg (Lond), 2014, 3(4) : 113 -116.
  • 8KeUey B. Industrialization tff mAb production technology: the bioprocessing industry at a crossroads[J]. MAbs, 2009, 1(5) : 443 -452.
  • 9Yokoyama WM, Christensen M, Santos GD, et al. Production of monoclonal antibodies [ J/OL ]. Curr Protoc Immunol, 2006, Chapter2: Unit 2.5. doi: 10. 1002/0471142735. im0205s74.
  • 10Friguet B, Chaffotte AF, Djavadi-Ohaniance L, et al. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay [ J ]. J Immunol Methods, 1985, 77(2) : 305 -319.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部